Targeting mutant KRAS in lung metastatic colon cancer using RNA technology
Mechanism and approach to inactivate mutant KRAS of lung metastatic colon cancer by RNA-ligand-displaying exosome to co-deliver dCas9--gRNA ribonucleoprotein complex and KRAS siRNA
This study is testing a new way to help people with aggressive lung cancer by using tiny particles to deliver treatments that can turn off a harmful gene called KRAS, which helps cancer grow, with the hope of improving their treatment outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10979756 on NIH RePORTER |
What this research studies
This research focuses on developing a novel RNA nanotechnology to target and silence the mutant KRAS gene, which is often responsible for aggressive forms of lung metastatic colon cancer. By utilizing exosomes to deliver a combination of gene-silencing agents and therapeutic drugs, the approach aims to improve treatment outcomes for patients with this challenging cancer type. The methodology involves creating a fusion protein that can specifically target and inhibit the expression of the mutant KRAS gene, which is crucial for cancer cell survival and proliferation. Patients may benefit from this innovative strategy that combines gene editing and drug delivery to combat cancer more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung metastatic colon cancer that harbors KRAS mutations.
Not a fit: Patients without KRAS mutations or those with other types of cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with lung metastatic colon cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using RNA-based technologies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Guo, Peixuan — Ohio State University
- Study coordinator: Guo, Peixuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.